trifolium pratense
Allergenexperimental
Trifolium pratense, red clover, is a herbaceous species of flowering plant in the bean family, Fabaceae. It is native to the Old World, but planted and naturalised in many other regions. — Wikipedia
Clinical trial activity
32 trials · 52 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
20
Phase 3
13
Phase 4
0
Earliest trial started Feb 1, 1996 (NCT00135642)
Timeline
Indications
Studied for
- Allergy and Immunology · Phase 2
- Asthma · Phase 3
- Conjunctivitis · Phase 3
- Conjunctivitis, Allergic · Phase 2
- Drugs, Investigational · Phase 2
- Healthy Volunteers · Phase 3
- Hot Flashes · Phase 2
- Hypersensitivity · Phase 2/Phase 3
- Immune Tolerance · Phase 2
- Menopause · Phase 2
- Pain · Phase 2
- Rhinitis · Phase 2/Phase 3
- Rhinitis, Allergic · Phase 3
- Rhinitis, Allergic, Seasonal · Phase 3
Mechanism of action
- Grass allergenImmunity, desensitized
Grass allergen immunity, desensitized
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTrifolium pratense ↗
- NCATS0P46LFE4VC ↗
- NCATS3SNK70F46Y ↗
Also known as
- alk phleum pratense
- alutard phleum pratense
- depigoid phleum
- phleum pratense allergen
- phleum pratense allergen extract
- phleum pretense allergen
- poa pratensis allergen extract
- p. pratense pollen extract
- sublivac fix phleum prat.
- trifolium pratense
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06061848 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2023 | Karolinska Institute |
| NCT04502966 | Phase 2 | Nov 9, 2020 | ALK-Abello, S.A., Immune Tolerance Network, Imperial College London, National Institute of Allergy and Infectious Diseases (NIAID), PPD, Regeneron, Rho, Inc. |
| NCT05191186 | Phase 3 | Feb 1, 2020 | Aarhus University, Linkoping University |
| NCT03205787 | N/A | Sep 21, 2017 | University of Illinois at Chicago |
| NCT02975479 | Phase 2/Phase 3 (Phase 3) | May 1, 2016 | Karolinska Institute, Lund University |
| NCT02556801 | Phase 2 | Sep 1, 2015 | HAL Allergy, Inflamax |
| NCT02849249 | Phase 1 | Sep 1, 2015 | Roxall Medizin |
| NCT02245360 | Phase 3 | Oct 1, 2014 | Abbott |
| NCT02166268 | Phase 2 | Jun 1, 2014 | ALK-Abello, S.A., Fraunhofer |
| NCT01924208 | Phase 3 | Oct 1, 2013 | Foundation for Paediatric Research, Finland, Government of Finland, Sigrid Juselius Foundation, University of Turku |
| NCT02255604 | Phase 2 | Aug 1, 2013 | Aarhus University |
| NCT03394508 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2013 | Karolinska Institute |
| NCT01634958 | Phase 2 | Oct 1, 2012 | Leti Pharma GmbH, University of Mannheim |
| NCT01682070 | Phase 2 | Sep 1, 2012 | HAL Allergy, University of Genoa |
| NCT01564017 | Phase 2 | May 1, 2012 | Badalona Hospital Germans Trias i Pujol, Hospital Blanca Paloma, Hospital de Manises, Hospital Vega Baja, Hospital Xeral Cies de Vigo, Osakidetza, Roxall Medizin, Universidad de Murcia, University of Cantabria, University of Santiago, University of Valencia |
| NCT01567306 | Phase 2 | Oct 1, 2011 | Centro Hospitalar de Vila Nova de Gaia/Espinho, Hospital da Universidade de Coimbra, Hospital Ntra. Sra. del Prado, Instituto CUF Porto, Roxall Medizin, Universidad Autonoma de Madrid, Universidad Complutense de Madrid |
| NCT01430117 | Phase 2 | Oct 1, 2011 | Leti Pharma GmbH |
| NCT01438827 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2011 | ALK-Abello, S.A. |
| NCT01425788 | Phase 2 | Aug 1, 2011 | ACM Global Laboratories, ALK-Abello, S.A., Brecon Pharmaceuticals Ltd, Ergomed, Medical University of Lodz |
| NCT01385371 | Phase 3 | Jun 1, 2011 | ALK-Abello, S.A. |
Showing 20 of 32 trials
Page 1 / 2
Organizations
Research & Development (52)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ALK-Abello, S.A. | For profit | 10 | 5 | 3 | 1996 |
| Leti Pharma GmbH | For profit | 5 | 4 | 2 | 2007 |
| Roxall Medizin | For profit | 4 | 4 | 2 | 2010 |
| Aarhus University | Academic/Hospital | 3 | 3 | 3 | 2010 |
| Karolinska Institute | Academic/Hospital | 3 | 3 | 1 | 2013 |
| University of Illinois at Chicago | Academic/Hospital | 3 | 1 | 3 | 2001 |
| HAL Allergy | For profit | 2 | 2 | 1 | 2012 |
| National Center for Complementary and Integrative Health (NCCIH) | Government | 2 | 2 | 2 | 2001 |
| Office of Dietary Supplements (ODS) | Government | 2 | 0 | 2 | 2001 |
| Universidad Complutense de Madrid | Academic/Hospital | 2 | 0 | 2 | 2010 |
| University of Copenhagen | Academic/Hospital | 2 | 2 | 2 | 2010 |
| University of London | Academic/Hospital | 2 | 2 | 1 | 1996 |
| Abbott | For profit | 1 | 1 | 1 | 2014 |
| ACM Global Laboratories | For profit | 1 | 0 | 1 | 2011 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Brecon Pharmaceuticals Ltd | For profit | 1 | 0 | 1 | 2011 |
| Centro Hospitalar de Vila Nova de Gaia/Espinho | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Ergomed | For profit | 1 | 0 | 1 | 2011 |
| Foundation for Paediatric Research, Finland | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Fraunhofer | For profit | 1 | 0 | 1 | 2014 |
52 organizations
Page 1 / 3